Lazard Asset Management’s AnaptysBio ANAB Stock Holding History

Lazard Asset Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,519	Closed	-$102K	–	2287
2025 Q1	$102K	Buy	+5,519	New	+$92.1K	﹤0.01%	1805
2022 Q1	–	Sell	-3,589	Closed	-$124K	–	2317
2021 Q4	$124K	Buy	3,589 +1,347	+60%	+$42.7K	﹤0.01%	1381
2021 Q3	$60K	Buy	+2,242	New	+$56.9K	﹤0.01%	1595
2021 Q2	–	Sell	-2,086	Closed	-$44K	–	1950
2021 Q1	$44K	Buy	+2,086	New	+$52.6K	﹤0.01%	1492

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Lazard Asset Management's ANAB Position: Q2 2025 in Review

Lazard Asset Management sold out of AnaptysBio (ANAB) in Q2 2025, closing a stake of 5,519 shares — an estimated $102K sold.

Lazard Asset Management first reported a position in ANAB in Q1 2021 and held it in 4 quarters. The position peaked at $124K in Q4 2021. 147 funds tracked by Wall St. Rank hold ANAB as of Q2 2025.

Lazard Asset Management reported no remaining AnaptysBio position as of Q2 2025 after selling out during the quarter.
Lazard Asset Management sold 5,519 AnaptysBio shares in Q2 2025, an estimated $102K.
Lazard Asset Management first reported a position in AnaptysBio in Q1 2021 and held it in 4 quarters.
Lazard Asset Management's AnaptysBio position peaked at $124K in Q4 2021.
147 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2025.

Based on Lazard Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.